Foundry Healthcare ShareIss1Y Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1LLY | ELI LILLY & CO | Healthcare | $1.11T | 31.85% |
2MRK | MERCK & CO INC | Healthcare | $314.90B | 9.03% |
3TMO | THERMO FISHER SCIENTIFIC INC | Healthcare | $197.88B | 5.67% |
4GILD | GILEAD SCIENCES INC | Healthcare | $166.72B | 4.78% |
5DHR | DANAHER CORP | Healthcare | $144.26B | 4.14% |
6VRTX | VERTEX PHARMACEUTICALS INC | Healthcare | $123.26B | 3.53% |
7ISRG | INTUITIVE SURGICAL INC | Healthcare | $122.33B | 3.51% |
8MCK | MCKESSON CORP | Healthcare | $101.14B | 2.90% |
9HCA | HCA HEALTHCARE INC | Healthcare | $82.34B | 2.36% |
10ELV | ELEVANCE HEALTH INC | Healthcare | $80.92B | 2.32% |
11CI | CIGNA GROUP | Healthcare | $74.45B | 2.14% |
12REGN | REGENERON PHARMACEUTICALS INC | Healthcare | $70.94B | 2.03% |
13CAH | CARDINAL HEALTH INC | Healthcare | $53.52B | 1.53% |
14EW | EDWARDS LIFESCIENCES CORP | Healthcare | $49.36B | 1.42% |
15IDXX | IDEXX LABORATORIES INC | Healthcare | $44.76B | 1.28% |
16BDX | BECTON DICKINSON & CO | Healthcare | $43.58B | 1.25% |
17A | AGILENT TECHNOLOGIES INC | Healthcare | $37.13B | 1.06% |
18IQV | IQVIA HOLDINGS INC | Healthcare | $34.42B | 0.99% |
19ZTS | ZOETIS INC | Healthcare | $32.10B | 0.92% |
20VEEV | VEEVA SYSTEMS INC | Healthcare | $31.74B | 0.91% |
21DXCM | DEXCOM INC | Healthcare | $29.58B | 0.85% |
22RMD | RESMED INC | Healthcare | $28.86B | 0.83% |
23GEHC | GE HEALTHCARE TECHNOLOGIES INC | Healthcare | $28.69B | 0.82% |
24ILMN | ILLUMINA INC | Healthcare | $28.24B | 0.81% |
25MTD | METTLER TOLEDO INTERNATIONAL INC | Healthcare | $26.47B | 0.76% |
26WST | WEST PHARMACEUTICAL SERVICES INC | Healthcare | $25.31B | 0.73% |
27DGX | QUEST DIAGNOSTICS INC | Healthcare | $23.32B | 0.67% |
28LH | LABCORP HOLDINGS INC | Healthcare | $23.24B | 0.67% |
29UTHR | UNITED THERAPEUTICS CORP | Healthcare | $22.74B | 0.65% |
30STE | STERIS PLC | Healthcare | $21.26B | 0.61% |
31VTRS | VIATRIS INC | Healthcare | $20.14B | 0.58% |
32ZBH | ZIMMER BIOMET HOLDINGS INC | Healthcare | $17.63B | 0.51% |
33THC | TENET HEALTHCARE CORP | Healthcare | $16.79B | 0.48% |
34DVA | DAVITA INC | Healthcare | $15.21B | 0.44% |
35EXEL | EXELIXIS INC | Healthcare | $14.06B | 0.40% |
36COO | COOPER COMPANIES INC | Healthcare | $13.99B | 0.40% |
37ALGN | ALIGN TECHNOLOGY INC | Healthcare | $12.66B | 0.36% |
38RVTY | REVVITY INC | Healthcare | $12.29B | 0.35% |
39MOH | MOLINA HEALTHCARE INC | Healthcare | $11.74B | 0.34% |
40PODD | INSULET CORP | Healthcare | $11.36B | 0.33% |
41EHC | ENCOMPASS HEALTH CORP | Healthcare | $11.13B | 0.32% |
42CRL | CHARLES RIVER LABORATORIES INTERNATIONAL INC | Healthcare | $10.81B | 0.31% |
43HSIC | HENRY SCHEIN INC | Healthcare | $10.00B | 0.29% |
44HALO | HALOZYME THERAPEUTICS INC | Healthcare | $9.23B | 0.26% |
45UHS | UNIVERSAL HEALTH SERVICES INC | Healthcare | $9.15B | 0.26% |
46ATR | APTARGROUP INC | Healthcare | $8.46B | 0.24% |
47TGTX | TG THERAPEUTICS INC | Healthcare | $8.40B | 0.24% |
48HQY | HEALTHEQUITY INC | Healthcare | $8.17B | 0.23% |
49BIO | BIO-RAD LABORATORIES INC | Healthcare | $8.15B | 0.23% |
50LNTH | LANTHEUS HOLDINGS INC | Healthcare | $7.00B | 0.20% |
51CHE | CHEMED CORP | Healthcare | $6.77B | 0.19% |
52HNGE | HINGE HEALTH INC | Healthcare | $6.74B | 0.19% |
53CAI | CARIS LIFE SCIENCES INC | Healthcare | $4.66B | 0.13% |
54LFST | LIFESTANCE HEALTH GROUP INC | Healthcare | $4.49B | 0.13% |
55NVST | ENVISTA HOLDINGS CORP | Healthcare | $4.35B | 0.12% |
56DOCS | DOXIMITY INC | Healthcare | $3.94B | 0.11% |
57HAE | HAEMONETICS CORP | Healthcare | $3.54B | 0.10% |
58OPCH | OPTION CARE HEALTH INC | Healthcare | $3.41B | 0.10% |
59ITGR | INTEGER HOLDINGS CORP | Healthcare | $3.24B | 0.09% |
60ASTH | ASTRANA HEALTH INC | Healthcare | $2.50B | 0.07% |
61PGNY | PROGYNY INC | Healthcare | $2.50B | 0.07% |
62PBH | PRESTIGE CONSUMER HEALTHCARE INC | Healthcare | $2.36B | 0.07% |
63MD | PEDIATRIX MEDICAL GROUP INC | Healthcare | $2.15B | 0.06% |
64OMCL | OMNICELL INC | Healthcare | $2.09B | 0.06% |
65AUPH | AURINIA PHARMACEUTICALS INC | Healthcare | $2.05B | 0.06% |
66CDNA | CAREDX INC | Healthcare | $2.05B | 0.06% |
67ADMA | ADMA BIOLOGICS INC | Healthcare | $2.02B | 0.06% |
68HCSG | HEALTHCARE SERVICES GROUP INC | Healthcare | $1.74B | 0.05% |
69ANAB | ANAPTYSBIO INC | Healthcare | $1.69B | 0.05% |
70INSP | INSPIRE MEDICAL SYSTEMS INC | Healthcare | $1.46B | 0.04% |
71CNMD | CONMED CORP | Healthcare | $1.30B | 0.04% |
72CERT | CERTARA INC | Healthcare | $1.08B | 0.03% |
73PCRX | PACIRA BIOSCIENCES INC | Healthcare | $1.01B | 0.03% |
74AMPH | AMPHASTAR PHARMACEUTICALS INC | Healthcare | $871M | 0.02% |
75HSTM | HEALTHSTREAM INC | Healthcare | $832M | 0.02% |
76CLYM | CLIMB BIO INC | Healthcare | $727M | 0.02% |
77EVH | EVOLENT HEALTH INC | Healthcare | $654M | 0.02% |
78TCMD | TACTILE SYSTEMS TECHNOLOGY INC | Healthcare | $648M | 0.02% |
79FLGT | FULGENT GENETICS INC | Healthcare | $573M | 0.02% |
80ARVN | ARVINAS INC | Healthcare | $517M | 0.01% |
81NRC | NRC HEALTH | Healthcare | $491M | 0.01% |
82VMD | VIEMED HEALTHCARE INC | Healthcare | $466M | 0.01% |
83PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $453M | 0.01% |
84DCTH | DELCATH SYSTEMS INC | Healthcare | $442M | 0.01% |
85CCRN | CROSS COUNTRY HEALTHCARE INC | Healthcare | $428M | 0.01% |
86EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $394M | 0.01% |
87ZNTL | ZENTALIS PHARMACEUTICALS INC | Healthcare | $364M | 0.01% |
88ELMD | ELECTROMED INC | Healthcare | $349M | 0.01% |
89UTMD | UTAH MEDICAL PRODUCTS INC | Healthcare | $222M | 0.01% |
90KROS | KEROS THERAPEUTICS INC | Healthcare | $211M | 0.01% |
91ANIK | ANIKA THERAPEUTICS INC | Healthcare | $203M | 0.01% |
92AMWL | AMERICAN WELL CORP | Healthcare | $199M | 0.01% |
93PDEX | PRO DEX INC | Healthcare | $183M | 0.01% |
94INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $180M | 0.01% |
95JYNT | JOINT CORP | Healthcare | $127M | 0.00% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $3.49T. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 99% toward Large, 66% toward Growth. +1% unclassified (4 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 95 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual68.4%Margin-6.6%No more than 25% of total assets may be invested in the securities of any one issuer.
Required<= 25.0%Actual31.8%Margin-6.8%
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 95 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 21%; both still land on the same side of the 2x limit.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 32.3% | -38.6% |
| 3 yearsp.a. | 5.0% | -20.0% |
| 5 yearsp.a. | 4.4% | 1.6% |
| 10 yearsp.a. | 8.8% | 3.4% |
| Since inceptionp.a. | 7.7% | -0.6% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 5.5% | -14.8% |
| 2025 | 10.0% | -32.5% |
| 2024 | 0.9% | -7.3% |
| 2023 | -1.9% | -13.6% |
| 2022 | 0.9% | 79.7% |
| 2021 | 25.4% | 82.1% |
| 2020 | 14.8% | 4.5% |
| 2019 | 19.2% | -16.4% |
| 2018 | 5.0% | 14.1% |
| 2017 | 19.7% | -9.0% |
| 2016 | -1.0% | 24.9% |
| 2015 | 7.2% | -2.6% |
| 2014 | 20.3% | -14.7% |
| 2013 | 42.0% | -3.7% |
| 2012 | 21.8% | -5.1% |
| 2011 | 10.9% | 8.2% |
| 2010 | 8.3% | 5.4% |
| 2009 | 22.4% | 5.5% |
| 2008 | -21.4% | 5.0% |
| 2007 | 4.5% | -4.0% |
| 2006 | 7.5% | 15.6% |
| 2005 | 10.3% | 18.4% |
| 2004 | 4.8% | -5.7% |
| 2003 | 11.3% | -27.2% |
| 2002 | -21.1% | 18.2% |
| 2001 | -15.9% | -4.9% |
| 2000 | 48.2% | -40.4% |
| 1999 | -14.4% | -13.4% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare ShareIss1Y Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a ShareIss1Y signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.